A cardiac glycoside epoxide, (−)-cryptanoside
A (1), was isolated from the stems of Cryptolepis
dubia collected in Laos, for which the complete structure
was confirmed
by analysis of its spectroscopic and single-crystal X-ray diffraction
data, using copper radiation at a low temperature. This cardiac glycoside
epoxide exhibited potent cytotoxicity against several human cancer
cell lines tested, including HT-29 colon, MDA-MB-231 breast, OVCAR3
and OVCAR5 ovarian cancer, and MDA-MB-435 melanoma cells, with the
IC50 values found to be in the range 0.1–0.5 μM,
which is comparable with that observed for digoxin. However, it exhibited
less potent activity (IC50 1.1 μM) against FT194
benign/nonmalignant human fallopian tube secretory epithelial cells
when compared with digoxin (IC50 0.16 μM), indicating
its more selective activity toward human cancer versus benign/nonmalignant
cells. (−)-Cryptanoside A (1) also inhibited Na+/K+-ATPase activity and increased the expression
of Akt and the p65 subunit of NF-κB but did not show any effects
on the expression of PI3K. A molecular docking profile showed that
(−)-cryptanoside A (1) binds to Na+/K+-ATPase, and thus 1 may directly target
Na+/K+-ATPase to mediate its cancer cell cytotoxicity.